https://www.selleckchem.com/pr....oducts/pmsf-phenylme
esponder versus progressor. Our study provides a deep cellular analysis of on-treatment changes during chemo-immunotherapy for advanced TNBC, demonstrating not only feasibility of single-cell analyses on serial tumor biopsies but also the heterogeneity of TNBC and differences in on-treatment changes in responder versus progressor.Hyperprolactinemia can have different causes physiological, pharmacological, and pathological. When investigating the etiology of hyperprolactinemia, clinicians need to be aware of se
Aimer
Commentaire
Partagez
